Compare SPFI & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPFI | PHAT |
|---|---|---|
| Founded | 1941 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 843.2M | 676.3M |
| IPO Year | 2019 | 2019 |
| Metric | SPFI | PHAT |
|---|---|---|
| Price | $44.25 | $7.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $46.00 | $19.83 |
| AVG Volume (30 Days) | 94.5K | ★ 1.0M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | 17.81 | ★ 42.72 |
| EPS | ★ 1.82 | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $22.65 | $93.04 |
| Revenue Next Year | $9.40 | $58.91 |
| P/E Ratio | $24.22 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $35.34 | $7.31 |
| 52 Week High | $46.94 | $18.31 |
| Indicator | SPFI | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.59 | 33.83 |
| Support Level | $44.05 | N/A |
| Resistance Level | $45.56 | $9.74 |
| Average True Range (ATR) | 0.79 | 0.45 |
| MACD | -0.06 | -0.12 |
| Stochastic Oscillator | 47.91 | 9.51 |
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.